LPCN

Lipocine Inc

Oct 17 • 04:00PM ET

3.02

-0.09 -2.89 %

Healthcare • Biotechnology • USA • NASD

Peers: AXSM CORT DVAX ENTA ANIP EOLS ARDX MNKD

Index	-	P/E	-	EPS (ttm)	-0.84	Insider Own	2.91%	Shs Outstand	5.37M	Perf Week	-2.58%
Market Cap	16.37M	Forward P/E	-	EPS next Y	-1.75	Insider Trans	0.00%	Shs Float	5.26M	Perf Month	7.47%
Enterprise Value	-1.57M	PEG	-	EPS next Q	-0.54	Inst Own	9.75%	Short Float	2.07%	Perf Quarter	-4.73%
Income	-4.51M	P/S	3.89	EPS this Y	-120554.55%	Inst Trans	0.26%	Short Ratio	3.30	Perf Half Y	0.67%
Sales	4.21M	P/B	0.95	EPS next Y	5.39%	ROA	-21.66%	Short Interest	0.11M	Perf YTD	-38.11%
Book/sh	3.19	P/C	0.91	EPS next 5Y	-	ROE	-23.51%	52W High	6.17 -51.04%	Perf Year	-40.55%
Cash/sh	3.31	P/FCF	-	EPS past 3/5Y	76.55% 82.03%	ROIC	-26.31%	52W Low	2.65 13.96%	Perf 3Y	-59.96%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	-11.47% 132.45%	Gross Margin	98.67%	Volatility	5.47% 5.59%	Perf 5Y	-87.66%
Dividend TTM	-	EV/Sales	-0.37	EPS Y/Y TTM	47.33%	Oper. Margin	-132.59%	ATR (14)	0.16	Perf 10Y	-98.58%
Dividend Ex-Date	-	Quick Ratio	12.71	Sales Y/Y TTM	-45.78%	Profit Margin	-107.11%	RSI (14)	48.89	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	12.71	EPS Q/Q	28.23%	SMA20	0.25%	Beta	1.24	Target Price	7.38
Payout	-	Debt/Eq	0.00	Sales Q/Q	595.42%	SMA50	1.30%	Rel Volume	0.37	Prev Close	3.11
Employees	16	LT Debt/Eq	0.00	Earnings	Aug 05 BMO	SMA200	-10.33%	Avg Volume	32.88K	Price	3.02
IPO	Jun 15, 2012	Option/Short	No / Yes	EPS/Sales Surpr.	-2.50% 171.97%	Trades		Volume	12,211	Change	-2.89%

Date	Action	Analyst	Rating Change	Price Target Change
Jun-24-21	Initiated	Cantor Fitzgerald	Overweight	$3
Dec-10-20	Upgrade	Ladenburg Thalmann	Neutral → Buy	$3
Jan-12-18	Reiterated	H.C. Wainwright	Buy	$10 → $3
Jan-11-18	Downgrade	Canaccord Genuity	Buy → Hold	$11 → $2
Dec-08-17	Resumed	H.C. Wainwright	Buy	$10
Oct-07-16	Initiated	H.C. Wainwright	Buy	$25
Jul-22-15	Initiated	ROTH Capital	Buy	$36
Jun-23-15	Initiated	Canaccord Genuity	Buy	$15

Sep-30-25 08:00AM	Lipocine Provides Progress Update on LPCN 1154 Phase 3 Clinical Trial in Postpartum Depression (PPD) (PR Newswire)
Sep-05-25 04:30PM	Lipocine to Present at H.C. Wainwright 27th Annual Global Investment Conference (PR Newswire)
Aug-26-25 08:00AM	Lipocine Announces LPCN 2101 Abstracts Accepted for Presentation at AES 2025 (PR Newswire)
Aug-05-25 08:00AM	Lipocine Announces Financial Results for the Second Quarter Ended June 30, 2025 (PR Newswire)
06:21AM	Lipocine: Q2 Earnings Snapshot (Associated Press Finance)
07:28AM	Loading…
Jun-27-25 07:28AM	Lipocine begins dosing in Phase III postpartum depression trial of LPCN 1154 (Clinical Trials Arena)
Jun-26-25 08:00AM	Lipocine Announces First Patient Dosed in Phase 3 Clinical Trial for LPCN 1154 in Postpartum Depression (PR Newswire)
Jun-23-25 08:00AM	Lipocine to Host Virtual R&D Investor Event to Discuss LPCN 1154 (BRLIZIO) as a Treatment for Postpartum Depression on July 9, 2025 (PR Newswire)
Jun-09-25 08:00AM	Lipocine Announces Filing of New Drug Submission for TLANDO in Canada (PR Newswire) +6.31%
May-22-25 08:00AM	Lipocine's LPCN 1148 Highlighted in the June 2025 Edition of Hepatology (PR Newswire)
May-14-25 08:00AM	Lipocine to Present at A.G.P.'s Annual Healthcare Company Showcase (PR Newswire) +10.10%
May-08-25 08:12AM	Lipocine: Q1 Earnings Snapshot (Associated Press Finance)
08:00AM	Lipocine Announces Financial Results for the First Quarter Ended March 31, 2025 (PR Newswire)
May-06-25 08:00AM	Lipocine Announces License and Supply Agreement for TLANDO in Brazil (PR Newswire)
Mar-27-25 12:03PM	Lipocines Phase III trial of LPCN 1154 to begin for postpartum depression (Clinical Trials Arena)
08:00AM	Loading…
Mar-26-25 08:00AM	Lipocine Announces Initiation of Outpatient Phase 3 Postpartum Depression Trial of LPCN 1154 (PR Newswire)
Mar-13-25 08:00AM	Lipocine Announces Financial Results for the Full Year Ended December 31, 2024 (PR Newswire)
Mar-12-25 08:00AM	Lipocine Announces FDA Labeling Changes for Testosterone Products (PR Newswire)
Feb-06-25 08:00AM	Lipocine Receives Updated Regulatory Guidance on LPCN 1154 (PR Newswire) -14.67%
Dec-17-24 08:00AM	FDA Grants Fast Track Designation to Lipocine for LPCN 1148 as a Treatment for Sarcopenia in Patients with Decompensated Cirrhosis (PR Newswire)
Nov-18-24 08:00AM	Lipocine Announces Publication and Discussion of LPCN 1148 Manuscript at The Liver Meeting 2024 Editor's Cut Session (PR Newswire)
Nov-07-24 08:00AM	Lipocine Announces Financial Results for the Third Quarter Ended September 30, 2024 (PR Newswire) -7.76%
06:25AM	Lipocine: Q3 Earnings Snapshot (Associated Press Finance)
Oct-31-24 08:00AM	Lipocine Announces Distribution and License Agreement with SPC Korea to Commercialize TLANDO in South Korea (PR Newswire)
Oct-10-24 08:00AM	Lipocine Announces Positive Oral Brexanolone Quantitative EEG Results (PR Newswire)
Oct-09-24 08:06AM	Lipocine signs supply and distribution agreement with Pharmalink for Tlando (TipRanks)
Oct-08-24 08:00AM	Lipocine Announces Supply and Distribution Agreement with Pharmalink to Commercialize TLANDO in the Gulf Cooperation Council (GCC) Countries (PR Newswire) +6.21%
Oct-02-24 08:00AM	Lipocine to Host Virtual KOL Event on LPCN 2401 for Improved Body Composition in Obesity Management on October 16, 2024 (PR Newswire)
Sep-30-24 08:00AM	Lipocine to Present at H.C. Wainwright 8th Annual MASH Investor Conference (PR Newswire)
Sep-05-24 08:00AM	Lipocine Announces Phase 2 Data on LPCN 2401 to be Presented at ObesityWeek (PR Newswire)
08:00AM	Loading…
Aug-27-24 08:00AM	Lipocine to Present at H.C. Wainwright 26th Annual Global Investment Conference (PR Newswire)
Aug-08-24 08:00AM	Lipocine Announces Financial Results for the Second Quarter Ended June 30, 2024 (PR Newswire) -12.90%
06:32AM	Lipocine: Q2 Earnings Snapshot (Associated Press Finance)
Jun-25-24 08:00AM	Lipocine Announces LPCN 1154 Meets Bioequivalence with IV Brexanolone in Pivotal Study (PR Newswire) -12.37%
Jun-10-24 08:00AM	Lipocine Presents 52 Week Results from LPCN 1148 Phase 2 Study in Late Breaking Session at EASL Congress 2024 (PR Newswire) +6.12%
Jun-06-24 08:50AM	Lipocine (LPCN) Is a Great Choice for 'Trend' Investors, Here's Why (Zacks)
May-28-24 06:10AM	7 Penny Biotech Stocks to Triple Your Investment (InvestorPlace)
May-21-24 08:50AM	Here's Why Momentum in Lipocine (LPCN) Should Keep going (Zacks)
May-09-24 01:53PM	LPCN Stock Earnings: Lipocine Beats EPS for Q1 2024 (InvestorPlace) +8.04%
08:00AM	Lipocine Announces Financial Results for the First Quarter Ended March 31, 2024 (PR Newswire)
06:24AM	Lipocine: Q1 Earnings Snapshot (Associated Press Finance)
May-08-24 08:00AM	Lipocine Announces Late Breaking Oral Presentation of Data from the Phase 2 Study of LPCN 1148 at EASL Congress 2024 (PR Newswire)
May-01-24 08:00AM	Lipocine Announces Completion of Dosing in Pivotal Study of Postpartum Depression Candidate, LPCN 1154 (PR Newswire)
Apr-11-24 07:00AM	Lipocine Announces Positive LPCN 2401 Clinical Results Showing Improved Body Composition in Participants with Obesity (PR Newswire)
Mar-28-24 08:00AM	Lipocine Announces Positive Week 52 Results from LPCN 1148 Phase 2 Study in Patients with Cirrhosis (PR Newswire)
Mar-25-24 08:00AM	Lipocine Announces First Cohort Dosed in Pivotal Study of LPCN 1154 (PR Newswire) +8.91%
Mar-07-24 02:52PM	LPCN Stock Earnings: Lipocine Beats EPS for Q4 2023 (InvestorPlace)
08:00AM	Lipocine Announces Financial Results for the Full Year Ended December 31, 2023 (PR Newswire)
Mar-06-24 08:00AM	Lipocine to Present at 36th Annual Roth Conference (PR Newswire)
Feb-06-24 08:00AM	Lipocine Announces Confirmation of Dosing Regimen for Pivotal Study of LPCN 1154 (PR Newswire)
Feb-02-24 08:00AM	Lipocine Announces Continued Commercialization of TLANDO through Verity Pharmaceuticals (PR Newswire)
Jan-18-24 08:00AM	Lipocine and Verity Pharma Enter into License Agreement for TLANDO Franchise in the U.S. and Canada (PR Newswire)
Dec-19-23 08:00AM	Lipocine to Present at Biotech Showcase 2024 (PR Newswire) +11.41%
Nov-13-23 02:45PM	Lipocine Releases Late Breaking Presentation on LPCN 1148 Phase 2 Results at The Liver Meeting 2023 (PR Newswire) +11.20%
Nov-08-23 08:17AM	Lipocine: Q3 Earnings Snapshot (Associated Press Finance)
08:00AM	Lipocine Announces Financial Results for the Third Quarter Ended September 30, 2023 (PR Newswire)
Nov-01-23 08:00AM	Lipocine to Present Clinical Data on LPCN 1148 at The Liver Meeting 2023 (PR Newswire)
Oct-26-23 08:00AM	Lipocine Completes Successful Meeting with FDA on LPCN 1154 in Postpartum Depression (PR Newswire)
Oct-23-23 07:00PM	Lipocine to Present at the H.C. Wainwright Annual NASH Investor Conference (PR Newswire)
Sep-19-23 04:05PM	Lipocine to Present at the Cantor Fitzgerald Global Healthcare Conference (PR Newswire) -6.12%
Aug-16-23 06:02AM	LPCN: Trial Results Improve Outlook (Zacks)
Aug-10-23 08:09AM	Lipocine: Q2 Earnings Snapshot (Associated Press Finance)
08:00AM	Lipocine Announces Financial Results for the Second Quarter Ended June 30, 2023 (PR Newswire)
Jul-31-23 06:13AM	LPCN: 1148 Shows Muscle Loss Reversal (Zacks)
Jul-27-23 06:30AM	LPCN 1148 Phase 2 Study Meets Primary Endpoint in Patients with Cirrhosis (PR Newswire) +18.60%
Jun-14-23 08:00AM	Lipocine to Present at H.C. Wainwright Annual Neuropsychiatry Virtual Conference (PR Newswire)
Jun-07-23 08:00AM	Lipocine to Present LPCN 1148 and LPCN 1144 at the EASL Congress 2023 (PR Newswire)
May-19-23 09:14AM	LPCN: 1154 Results Illuminate Accelerated Pathway (Zacks Small Cap Research)
May-16-23 07:00AM	Positive Topline Clinical Results Support Streamlined Development Pathway for LPCN 1154, Lipocine's Oral Candidate for Rapid Relief of Depression (PR Newswire) -17.72%
May-11-23 06:23AM	Lipocine: Q1 Earnings Snapshot (AP Finance) +7.30%
06:00AM	Lipocine Announces Financial Results for the First Quarter Ended March 31, 2023 (PR Newswire)
Apr-03-23 08:00AM	First Subject Dosed in the Clinical Bridge Study with Lipocine Depression Candidate, LPCN 1154 (PR Newswire)
Mar-16-23 06:00AM	LPCN: 2022 Operational & Financial Update (Zacks Small Cap Research) +9.55%
Mar-10-23 08:30AM	Lipocine Announces Pro Rata Distribution of Series B Preferred Stock to its Holders of Common Stock (PR Newswire) -26.79%
08:30AM	Lipocine Announces Financial Results for the Year Ended December 31, 2022 (PR Newswire)
Jan-16-23 08:06AM	Is Lipocine Inc.'s (NASDAQ:LPCN) Stock's Recent Performance Being Led By Its Attractive Financial Prospects? (Simply Wall St.)
Jan-05-23 08:00AM	Lipocine to Present at Biotech Showcase (PR Newswire)
Dec-19-22 08:00AM	Lipocine Completes Enrollment of LPCN 1148 Phase 2 Study for Decompensated Cirrhosis (PR Newswire) +5.62%
Nov-30-22 04:28AM	LPCN: Focus on CNS Disorders (Zacks Small Cap Research)
Nov-09-22 08:00AM	Lipocine Announces Financial Results for the Third Quarter Ended September 30, 2022 (PR Newswire) -5.98%
Nov-03-22 08:00AM	Lipocine Announces Senior Leadership Appointments to Advance its CNS-Focused Pipeline (PR Newswire)
Oct-11-22 08:00AM	Lipocine to Present at H.C. Wainwright 6th Annual NASH Investor Conference (PR Newswire)
Sep-27-22 01:21PM	Lipocine to Participate in the Cantor Neurology & Psychiatric Conference (PR Newswire) -11.85%
Sep-26-22 11:39AM	Lipocine To Focus On Central Nervous System Conditions; Explores Partnerships For Non-Core Assets (Benzinga) -10.41%
08:00AM	Lipocine Announces Strategic Realignment and Forward Focus on Treating CNS Disorders (PR Newswire)
Sep-22-22 04:10PM	Lipocine to Present at Ladenburg Thalmann 2022 Healthcare Conference (PR Newswire)
Sep-15-22 08:00AM	Lipocine Announces Favorable Regulatory Pathway on Oral LPCN 1154 for Post-Partum Depression (PPD) (PR Newswire) +5.69%
Aug-10-22 06:04AM	LPCN: TLANDO Launched (Zacks Small Cap Research)
Aug-09-22 06:41AM	Lipocine Inc. (NASDAQ:LPCN) Stock's Been Sliding But Fundamentals Look Decent: Will The Market Correct The Share Price In The Future? (Simply Wall St.)
Aug-08-22 08:00AM	Lipocine Announces Financial Results for the Second Quarter Ended June 30, 2022 (PR Newswire) -11.09%
Jul-11-22 08:00AM	FDA Clears LPCN 2101 IND for Adult Epilepsy Treatment (PR Newswire)
Jun-14-22 08:00AM	LIPOCINE GRANTED US PATENTS DIRECTED TO CNS AND LIVER PROGRAMS (PR Newswire)
Jun-06-22 04:00PM	LIPOCINE ANNOUNCES PRESENTATION AT 2022 EPILEPSY FOUNDATION PIPELINE CONFERENCE (PR Newswire) +10.05%
May-20-22 07:12AM	LPCN: OLE Results (Zacks Small Cap Research)
May-12-22 10:55AM	Lipocine Posts Encouraging Data For Testosterone Prodrug In NASH Patients (Benzinga)
08:00AM	Lipocine Announces Positive LPCN 1144 NASH Open Label Extension Study Results (PR Newswire)
May-10-22 11:30AM	LPCN: First Quarter 2022 Financial and Operational Results (Zacks Small Cap Research)
May-09-22 08:00AM	Lipocine Announces Financial Results for the First Quarter Ended March 31, 2022 (PR Newswire)
May-04-22 06:34AM	Shareholders in Lipocine (NASDAQ:LPCN) are in the red if they invested five years ago (Simply Wall St.)
Apr-11-22 08:00AM	LIPOCINE ANNOUNCES BOARD of DIRECTOR APPOINTMENTS (PR Newswire)

Lipocine, Inc. is a clinical-stage biopharmaceutical company, which engages in the research and development of the delivery of drugs using proprietary delivery technology. It offers TLANDO, an oral testosterone replacement therapy. The company was founded on October 13, 2011 and is headquartered in Salt Lake City, UT.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

LPCN

Lipocine Inc

Upgrade your FINVIZ experience